论文部分内容阅读
创业阶段拒绝了两次外部投资;而现在,他们为什么甘愿放弃控股权,与体量庞大的跨国巨头合作对于刚接触生物疫苗创业公司的人来说,云南沃森生物技术有限公司看起来不像创业企业,倒像是一个新药批发商:通过自主创新,迄今它已研发成功9个新药(疫苗)品种,其中3项为国家863重大科技攻关课题,在国内疫苗企业尚无先例.公司自主“,”Listed as one of the 21 Stars of the future,Walvax Biotech Co.Ltd does not resemble other venture businesses,but looks like a wholesale dealer of new medicines.So far,Walvax has invented 8 new drugs,one first-class level,one of second-class,and six in other categories. In October 2009,Walvax and GlaxoSmithKline(GSK),the world's largest vaccine-maker,formed a joint venture.The former gets 35 percent of the joint venture and the latter 65 percent.Data has shown that the vaccine market accounts for 2.5 percent of the entire pharmaceutical market in the U.S.while its counterpart figure in China is 0.7%.Li Yunchu,the President of Walvax believes that“the vaccine market will definitely be growing fast in the coming 8 to 10 years.”